Foghorn Therapeutics (NASDAQ:FHTX) remains a "hold" rating based on the fact that it is in the process of developing its lead candidate FHD-909 for the treatment of solid tumor patients who ...

Investing.com — El miércoles, JMP Securities inició la cobertura de Foghorn Therapeutics (NASDAQ:FHTX), que actualmente cotiza a 4,24 dólares y muestra un fuerte impulso con una ganancia del ...

Dell EMC is partnering with edge intelligence startup FogHorn to sell out-of-the-box industrial Internet of Things hardware and software bundles. The collaboration, announced Tuesday, will provide ...